Recent Advances in Diabetic Retinopathy: MRCP Ophthalmology Update

Diabetic retinopathy (DR) remains the leading cause of preventable blindness in working-age adults in the UK — and it is quietly becoming one of the most examinable crossover topics in the MRCP syllabus. It sits at the intersection of endocrinology, ophthalmology, nephrology and preventive medicine, which is exactly the kind of integrated territory the Royal College of Physicians loves to test in Best-of-Five questions and occasionally probe in PACES Station 5.

What has changed dramatically in recent years is the evidence base: anti-VEGF therapy has overturned decades of laser-first dogma, systemic cardiometabolic drugs are now showing retinal benefits, and autonomous AI screening devices have entered clinical practice. If your knowledge of DR stopped at 'panretinal photocoagulation for proliferative disease', this update is for you.

Why Diabetic Retinopathy Deserves Your Revision Time

• Prevalence: Retinopathy affects roughly one in three people with diabetes, with sight-threatening disease in up to 1 in 15.

• Systemic marker: The retina is the only place in the body where microvasculature can be directly visualised. DR severity independently predicts CKD progression, stroke and cardiovascular mortality — a favourite MRCP discriminator.

• Screening programme: The NHS Diabetic Eye Screening Programme (DESP) is one of the largest population screening programmes in the world, and its referral thresholds are examinable.

• Therapeutic revolution: Between 2015 and 2024, landmark trials (Protocol S, Protocol T, CLARITY, YOSEMITE/RHINE, LENS) rewrote the management pathway.

Classification Refresher: The 4-2-1 Rule

Before the new stuff, make sure the foundations are solid — examiners still expect you to stage disease accurately.

Exam pearl: Maculopathy and proliferative disease are independent processes. A patient with mild background retinopathy can still blinding diabetic macular oedema.

Recent Advance 1: Anti-VEGF Therapy Has Replaced Laser as First-Line for Centre-Involving DMO

This is the single most important shift in management.

Protocol T (DRCR Network, 2015)

• Compared aflibercept, bevacizumab and ranibizumab for centre-involving DMO.

• All three were effective, but aflibercept was superior when baseline visual acuity was poor (worse than approximately 6/12).

• Exam pearl: If a vignette describes a patient with diabetes and vision of 6/60 plus centre-involving DMO, the best answer is intravitreal aflibercept, not laser.

Faricimab — The First Dual-Target Angiogenic Agent (YOSEMITE/RHINE, Lancet 2022)

• Faricimab targets both VEGF-A and angiopoietin-2, allowing an extended dosing interval.

• In DMO, faricimab every 8 weeks (after loading) was non-inferior to aflibercept every 8 weeks, with roughly half of patients extending to 12- or 16-weekly intervals.

• Relevance: Fewer injections mean fewer hospital visits — a genuine systems-level benefit MRCP questions increasingly acknowledge.

Brolucizumab (KESTREL/KITE)

• A smaller-molecule anti-VEGF with higher molar dosing; approved for DMO in several jurisdictions on the back of non-inferiority to aflibercept with extended-interval dosing.

• Watch for the exam-friendly fact that it carries a small risk of intraocular inflammation.

Steroid Implants

• Dexamethasone implant (Ozurdex) and fluocinolone acetonide implant (Iluvien) are second-line options, particularly in pseudophakic eyes or patients unsuitable for anti-VEGF.

• Exam pearl: Steroid implants raise intraocular pressure and accelerate cataract — a classic pharmacology crossover question.

Recent Advance 2: Proliferative Disease — Anti-VEGF vs Panretinal Photocoagulation

Protocol S (2015)

• Intravitreal ranibizumab was non-inferior to panretinal photocoagulation (PRP) for proliferative DR, with better average visual acuity, less visual field loss and fewer vitrectomies.

CLARITY (Lancet, 2017)

• Aflibercept was superior to PRP for best-corrected visual acuity at 52 weeks in proliferative DR.

What the examiner wants you to know: PRP remains a valid, durable, one-off treatment — but anti-VEGF is now an evidence-based alternative or bridge, especially where coexisting DMO threatens central vision or the patient needs cataract/vitreoretinal surgery. In real UK practice, a combined approach is common.

Recent Advance 3: Systemic Drugs Protecting the Retina

This is where MRCP questions get genuinely interesting, because the prescriber — you, the physician — is the intervention.

Fenofibrate: From Curiosity to Guideline-Worthy Evidence

• FIELD (2005): fenofibrate reduced the need for laser therapy by ~30% in type 2 diabetes, independent of lipid effects.

• ACCORD Eye (2010): fenofibrate plus simvastatin slowed DR progression by ~40%.

• LENS Trial (NEJM 2023): In type 2 diabetes with early retinopathy, fenofibrate significantly reduced progression to sight-threatening disease or the need for intervention — the cleanest evidence yet.

• Exam pearl: A BOF question about add-on therapy for progressive retinopathy despite good glycaemic and BP control in a patient with modest hypertriglyceridaemia points to fenofibrate — not pioglitazone, not a higher statin dose.

Metabolic Legacy Effect (DCCT/EDIC)

• Early intensive glycaemic control produces a metabolic memory effect — sustained reduction in retinopathy progression decades later, even after control equalises between groups.

• Contrast this with early worsening: rapid tightening of control in chronic hyperglycaemia can transiently worsen retinopathy in the first 6–12 months (a recognised phenomenon from DCCT). Reassure patients this is monitored — never use it as a reason to avoid good control.

GLP-1 Receptor Agonists and Dual Agonists

• Semaglutide: Rapid, profound glycaemic improvement has been associated in observational data with early DR worsening in a small proportion of patients — current practice is to screen before initiation or promptly after, not to withhold therapy.

• Tirzepatide (SURPASS-CVOT, 2023): Dual GIP/GLP-1 agonist was associated with a reduced incidence of DR progression events — a headline-worthy positive signal.

• Exam framing: Expect questions testing whether you know GLP-1 therapy is continued, with ophthalmic surveillance, rather than stopped.

Blood Pressure and Lipids

• UKPDS: tight BP control reduced retinopathy progression by ~34% — the legacy trial every candidate must know.

• Statins remain standard for cardiovascular indications; their retinal benefit is modest and indirect.

Recent Advance 4: AI-Assisted Screening Has Arrived

• IDx-DR became the first FDA-authorised autonomous AI diagnostic system in any field of medicine (2018) — it screens fundus photographs for more-than-mild DR without a clinician interpreting the image.

• EyeArt (CE-marked) demonstrates >95% sensitivity for referable DR and very high sensitivity for vision-threatening DR in validation cohorts.

• The NHS DESP increasingly explores AI triage to reduce grading workload; a 2023 National Screening Committee review supported further implementation.

Exam angle: Questions may test the principle that AI screening for DR has high sensitivity but imperfect specificity — meaning AI-positive images still route to human graders, and a negative screen still requires repeat annual recall. Understand the reasoning, not just the brand names.

Screening and Referral Thresholds: The NICE/NHS Framework

Screening basics to memorise: annual digital retinal photography from 12 years old (type 1) or from diagnosis (type 2); pregnant patients with pre-existing diabetes need screening at booking, ~28 weeks and postpartum — a beloved question because gestational diabetes does not require retinal screening.

How MRCP Actually Tests This Topic

Recognise these five recurring patterns:

1. The referral decision: 'New vessels on fundoscopy — what is the most appropriate next step?' → Immediate ophthalmology referral (not next DESP round, not an FFA request by you).

2. The DMO management choice: Centre-involving DMO with poor vision → intravitreal anti-VEGF (aflibercept if vision poor), not focal laser as first-line.

3. The systemic therapy add-on: Progressive retinopathy despite HbA1c and BP at target → consider fenofibrate.

4. The early-worsening trap: Retinopathy deteriorates 4 months after starting intensive insulin → known phenomenon, continue therapy, ensure ophthalmic monitoring.

5. The prognostic marker: Severe retinopathy as a flag for concurrent nephropathy — expect the question to ask about checking urine ACR and eGFR.

Sample Vignette (BOF-Style)

A 58-year-old man with type 2 diabetes (duration 14 years, HbA1c 74 mmol/mol) attends DESP. Grading shows extensive intraretinal haemorrhages in all four quadrants, venous beading in two quadrants and IRMAs. What is the single most important next step?

Answer: Urgent referral to ophthalmology — this is severe NPDR bordering on proliferative disease requiring specialist assessment within weeks. The distractors (optimising glycaemia, adding fenofibrate, annual recall) are all correct actions but not the most urgent next step — a classic MRCP sequencing lesson.

PACES Relevance: The Fundoscopy Finding You Must Not Miss

In Station 5 or a Station 2 discussion, you may be handed fundoscopic findings or a photo:

• Describe systematically: disc, vessels, haemorrhages (dot-blot vs flame), exudates (hard vs cotton wool spots), macula.

• Interpret systemically: state that you would examine for the other microvascular complications — urinalysis for ACR, feet review, cardiovascular assessment, BP.

• Manage as a physician: address the seven modifiable factors — glycaemia, blood pressure, lipids, smoking, renal function, medication review (e.g., is this patient on fenofibrate territory?), and screening compliance.

Saying 'I would also check renal function, as retinopathy severity predicts nephropathy' is precisely the joined-up thinking that earns marks.

Key Takeaways for the Exam

Final Thoughts

Diabetic retinopathy has transformed from a 'laser and hope' specialty into a showcase of modern medicine: targeted biologics, repositioned cardiometabolic drugs and machine-learning screening. For the MRCP candidate, this topic rewards those who see the retina as a window on systemic disease. Learn the trial names, understand why each shift happened, and always anchor your answer to the safest next step — because that is exactly what the College is testing.

Keep revising smart, connect the systems, and let the fundus tell you the story of the whole patient.